Join
Live feed
·
PRReleasevia Quantisnow
Longboard Pharmaceuticals Inc. logo

Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)

ByQuantisnow·Wall Street's wire, on your screen.
LBPH· Longboard Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LBPH (Longboard Pharmaceuticals Inc.) and more on Quantisnow.